Literature DB >> 34889396

Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond.

Karlyn A Martin1, Michael J Cuttica2,3.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication in pulmonary embolism (PE) survivors, characterized by chronic vascular occlusion and pulmonary hypertension. The identification and diagnosis of CTEPH requires a stepwise approach, starting with symptom evaluation, functional evaluation, screening imaging, and progressing to interventional hemodynamic assessment. On the backbone of anticoagulation, CTEPH management necessitates a multidisciplinary approach. Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative option. In nonoperable disease or residual disease after PTE, interventional balloon pulmonary angioplasty and/or pulmonary-vasodilator therapies can be offered, in collaboration with interventional and vascular pulmonary colleagues. As it is a disease that can cause high morbidity and mortality, CTEPH requires a high index of suspicion to diagnose and treat in patients following PE.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34889396      PMCID: PMC8791133          DOI: 10.1182/hematology.2021000282

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  43 in total

1.  A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension.

Authors:  Katherine Bunclark; Michael Newnham; Yi-Da Chiu; Alessandro Ruggiero; Sofia S Villar; John E Cannon; Gerry Coghlan; Paul A Corris; Luke Howard; David Jenkins; Martin Johnson; David G Kiely; Choo Ng; Nicholas Screaton; Karen Sheares; Dolores Taboada; Steven Tsui; Stephen John Wort; Joanna Pepke-Zaba; Mark Toshner
Journal:  J Thromb Haemost       Date:  2019-10-18       Impact factor: 5.824

2.  Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.

Authors:  John E Cannon; Li Su; David G Kiely; Kathleen Page; Mark Toshner; Emilia Swietlik; Carmen Treacy; Anie Ponnaberanam; Robin Condliffe; Karen Sheares; Dolores Taboada; John Dunning; Steven Tsui; Choo Ng; Deepa Gopalan; Nicholas Screaton; Charlie Elliot; Simon Gibbs; Luke Howard; Paul Corris; James Lordan; Martin Johnson; Andrew Peacock; Robert MacKenzie-Ross; Benji Schreiber; Gerry Coghlan; Kostas Dimopoulos; Stephen J Wort; Sean Gaine; Shahin Moledina; David P Jenkins; Joanna Pepke-Zaba
Journal:  Circulation       Date:  2016-04-06       Impact factor: 29.690

3.  Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients.

Authors:  Michael M Madani; William R Auger; Victor Pretorius; Naohide Sakakibara; Kim M Kerr; Nick H Kim; Peter F Fedullo; Stuart W Jamieson
Journal:  Ann Thorac Surg       Date:  2012-05-23       Impact factor: 4.330

4.  An international physician survey of chronic thromboembolic pulmonary hypertension management.

Authors:  Henning Gall; Ioana R Preston; Barbara Hinzmann; Sabina Heinz; David Jenkins; Nick H Kim; Irene Lang
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

5.  Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.

Authors:  Roela Sadushi-Kolici; Pavel Jansa; Grzegorz Kopec; Adam Torbicki; Nika Skoro-Sajer; Ioana-Alexandra Campean; Michael Halank; Iveta Simkova; Kristof Karlocai; Regina Steringer-Mascherbauer; Miroslav Samarzija; Barbara Salobir; Walter Klepetko; Jaroslav Lindner; Irene M Lang
Journal:  Lancet Respir Med       Date:  2018-11-23       Impact factor: 30.700

Review 6.  An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan.

Authors:  Henning Gall; Marius M Hoeper; Manuel J Richter; William Cacheris; Barbara Hinzmann; Eckhard Mayer
Journal:  Eur Respir Rev       Date:  2017-03-29

7.  Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature.

Authors:  Yvonne M Ende-Verhaar; Suzanne C Cannegieter; Anton Vonk Noordegraaf; Marion Delcroix; Piotr Pruszczyk; Albert T A Mairuhu; Menno V Huisman; Frederikus A Klok
Journal:  Eur Respir J       Date:  2017-02-23       Impact factor: 16.671

8.  Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data.

Authors:  M Riedel; V Stanek; J Widimsky; I Prerovsky
Journal:  Chest       Date:  1982-02       Impact factor: 9.410

9.  Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study.

Authors:  Susan R Kahn; Andrew M Hirsch; Arash Akaberi; Paul Hernandez; David R Anderson; Philip S Wells; Marc A Rodger; Susan Solymoss; Michael J Kovacs; Lawrence Rudski; Avi Shimony; Carole Dennie; Christopher Rush; William H Geerts; Shawn D Aaron; John T Granton
Journal:  Chest       Date:  2016-12-06       Impact factor: 9.410

10.  Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.

Authors:  Josep Ordi-Ros; Luis Sáez-Comet; Mercedes Pérez-Conesa; Xavier Vidal; Antoni Riera-Mestre; Antoni Castro-Salomó; Jordi Cuquet-Pedragosa; Vera Ortiz-Santamaria; Montserrat Mauri-Plana; Cristina Solé; Josefina Cortés-Hernández
Journal:  Ann Intern Med       Date:  2019-10-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.